142 related articles for article (PubMed ID: 10342092)
21. Contraceptive choices in women with coagulation disorders.
Comp PC; Zacur HA
Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 2):1990-3. PubMed ID: 8512043
[TBL] [Abstract][Full Text] [Related]
22. Alesse: leading the shift to 20 microg.
Archer DF
Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):37-8. PubMed ID: 10561673
[No Abstract] [Full Text] [Related]
23. Progestogens in cardiovascular diseases: an introduction to the epidemiologic data.
Mann JI
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):752-7. PubMed ID: 7065056
[TBL] [Abstract][Full Text] [Related]
24. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
Akerlund M
Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
[TBL] [Abstract][Full Text] [Related]
26. The 150/30 formulation. Experience in the United Kingdom.
Guillebaud J
J Reprod Med; 1983 Jan; 28(1 Suppl):66-70. PubMed ID: 6403702
[TBL] [Abstract][Full Text] [Related]
27. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
28. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
29. Contraceptive Steroids, age, and the cardiovascular system.
Plunkett ER
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):747-51. PubMed ID: 7065055
[TBL] [Abstract][Full Text] [Related]
30. Ovarian function during low-dose oral contraceptive use.
Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
[TBL] [Abstract][Full Text] [Related]
31. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
32. Oral contraceptive use and myocardial infarction.
Petitti DB; Sidney S; Quesenberry CP
Contraception; 1998 Mar; 57(3):143-55. PubMed ID: 9617531
[TBL] [Abstract][Full Text] [Related]
33. Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives.
Roy S
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S364-8. PubMed ID: 10368522
[TBL] [Abstract][Full Text] [Related]
34. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
[TBL] [Abstract][Full Text] [Related]
35. Hemostatic effects of smoking and oral contraceptive use.
Fruzzetti F
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S369-74. PubMed ID: 10368523
[TBL] [Abstract][Full Text] [Related]
36. The estrogen component of OCs: cardiovascular benefits and risks.
Burkman RT
Int J Fertil Womens Med; 1997; Suppl 1():145-57. PubMed ID: 9168374
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke.
Castelli WP
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S349-56. PubMed ID: 10368520
[TBL] [Abstract][Full Text] [Related]
38. [Vascular disease and hormonal treatment--epidemiology].
Vessey MP
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):121-6. PubMed ID: 12280197
[TBL] [Abstract][Full Text] [Related]
39. Hormonal contraception: benefits versus risks.
Goldzieher JW
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1023-8. PubMed ID: 3674179
[TBL] [Abstract][Full Text] [Related]
40. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
